

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	KOREN ET AL.	Examiner:	L. SPECTOR
Serial No.:	10/731,595	Group Art Unit:	1647
Filed:	DECEMBER 8, 2003	Docket No.:	11669.72USD1
Title:	IDENTIFICATION AND MODIFICATION OF IMMUNODOMINANT EPITOPES IN POLYPEPTIDES		

---

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**

PATENT TRADEMARK OFFICE

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

**Certification Under 37 C.F.R. §1.97(e)(1)**

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that each item of information listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart foreign application within three months of filing this statement.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: July 27, 2006

Katherine M. Kowalchuk  
Katherine M. Kowalchuk  
Reg. No. 36,848  
KMK:PLSkaw

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.72USD1	Application Number: 10/731,595
	Applicant: KOREN ET AL.	
	Filing Date: 12/08/2003	Group Art Unit: 1047

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Algiman, M. et al., "Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 3795-3799 (May 1992)
		Lubin, I. et al., "Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis," <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 48, pp. 30191-30195 (November 28, 1997)
		Revolletta, R. et al., "Natural and Therapeutically-Induced Antibodies to Cytokines," <i>Biotherapy</i> , Vol. 10, pp. 321-331 (1998)
		Shiozaki, H. et al., "Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura," <i>Blood</i> , Vol. 95, No. 6, pp. 2187-2188 (March 15, 2000)

<b>23552</b> PATENT TRADEMARK OFFICE
---

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	